Evidence map›Paper›PMID 31366895›Full record

ArticleScientific reports2019

Comparative Study of Subcutaneous and Orthotopic Mouse Models of Prostate Cancer: Vascular Perfusion, Vasculature Density, Hypoxic Burden and BB2r-Targeting Efficacy.

Wenting Zhang, Wei Fan, Satyanarayana Rachagani, Zhengyuan Zhou, Subodh M Lele, Surinder K Batra, Jered C Garrison

Open access · goldAbstract readComparative Study
In one paragraph

Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed
3.6field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 70 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Glypican-3-targeted immunoPET imaging of hepatocellular carcinoma: a translational study.European journal of nuclear medicine and molecular imaging · 2026
    Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Targeting Extra Domain A of Fibronectin to Improve Noninvasive Detection of Triple-Negative Breast Cancer.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025
    Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Oral Carbon Monoxide Enhances Autophagy Modulation in Prostate, Pancreatic, and Lung Cancers.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Wenting ZhangDepartment of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, NE, USA.
Wei FanDepartment of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, NE, USA.
Satyanarayana RachaganiDepartment of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE, USA.
Zhengyuan ZhouDepartment of Radiology, Duke University Medical Center, Durham, NC, USA.
Subodh M LeleDepartment of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE, USA.
Surinder K BatraEppley Cancer Center, University of Nebraska Medical Center, Omaha, NE, USA.
Jered C GarrisonDepartment of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, NE, USA. jcgarrison@unmc.edu.
University of Nebraska Medical Center · USDuke Medical Center · US

Funding

Enhancement of BB2r-Targeted Radiotherapy for Prostate Cancer Utilizing Hypoxia-SR01CA179059 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI GARRISON, JERED C · 2014 to 2018
$1.6M
NCI NIH HHS R01 CA179059
6 · The paper itself

Abstract

The gastrin-releasing peptide receptor (BB2r) is overexpressed in a variety of cancers including prostate cancer. As a consequence, the development of BB2r-targeted diagnostic/therapeutic radiopharmaceuticals has been widely explored. Both subcutaneous and orthotopic mouse models have been extensively used in BB2r-targeted agent development, but side-by-side studies examining how biological parameters (tumor perfusion efficacy, hypoxic burden and microvasculature density) impact BB2r-targeted agent delivery has not been reported. Herein, we examine these biological parameters using subcutaneous and orthotopic PC-3 xenografts. Using a dual isotope biodistribution study, tumor perfusion was accessed using [

Indexed as

AnimalsAntineoplastic AgentsAutoradiographyDisease Models, AnimalFemaleHypoxiaLutetiumMaleMiceMice, Inbred NODMice, SCIDProstatic NeoplasmsRadionuclide ImagingRadiopharmaceuticalsReceptors, BombesinTissue DistributionAntineoplastic AgentsLutetiumRadiopharmaceuticalsReceptors, Bombesin

Identifiers

PMID31366895
PMCPMC6668441
OpenAlexW2966662159

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.